EA202193150A2 - Филовирусная вакцина на основе рекомбинантного модифицированного вируса осповакцины анкара (mva) - Google Patents

Филовирусная вакцина на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)

Info

Publication number
EA202193150A2
EA202193150A2 EA202193150A EA202193150A EA202193150A2 EA 202193150 A2 EA202193150 A2 EA 202193150A2 EA 202193150 A EA202193150 A EA 202193150A EA 202193150 A EA202193150 A EA 202193150A EA 202193150 A2 EA202193150 A2 EA 202193150A2
Authority
EA
Eurasian Patent Office
Prior art keywords
mva
recombinant
relates
vaccino
basis
Prior art date
Application number
EA202193150A
Other languages
English (en)
Inventor
Ариане Фолькманн
Робин Штайгервальд
Хубертус Хохрайн
Ульрике Дирмайер
Хеннинг Лаутербах
Юрген Хаусманн
Original Assignee
Бавариан Нордик А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бавариан Нордик А/С filed Critical Бавариан Нордик А/С
Publication of EA202193150A2 publication Critical patent/EA202193150A2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Настоящее изобретение связано с усовершенствованной филовирусной вакциной, содержащей вакцину на основе рекомбинантного модифицированного вируса осповакцины Анкара (MVA основе) против филовирусной инфекции и имеющие к ней отношения продукты, способы и применения. В частности, настоящее изобретение связано с генетически спроектированными (рекомбинантными) векторами MVA и FPV, содержащими по меньшей мере одну гетерологичную нуклеотидную последовательность, кодирующую антигенную детерминанту гликопротеина вируса Марбург (MARV) или вируса Эбола. В частности, изобретение связано с рекомбинантным MVA, содержащим гликопротеин вируса Эбола и белок 40 вириона. Изобретение также связано с продуктами, способами и их применениями, также как и с примирующими/бустирующими режимами MVA и генетически спроектированными (рекомбинантными) FPV, например, подходящими для вызова защитного иммунного ответа у субъекта.
EA202193150A 2014-09-25 2015-09-03 Филовирусная вакцина на основе рекомбинантного модифицированного вируса осповакцины анкара (mva) EA202193150A2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462055154P 2014-09-25 2014-09-25

Publications (1)

Publication Number Publication Date
EA202193150A2 true EA202193150A2 (ru) 2022-03-31

Family

ID=81077500

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202193150A EA202193150A2 (ru) 2014-09-25 2015-09-03 Филовирусная вакцина на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)
EA201790506A EA039715B1 (ru) 2014-09-25 2015-09-03 Филовирусная вакцина на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201790506A EA039715B1 (ru) 2014-09-25 2015-09-03 Филовирусная вакцина на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)

Country Status (1)

Country Link
EA (2) EA202193150A2 (ru)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3639851A1 (en) * 2012-09-04 2020-04-22 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses

Also Published As

Publication number Publication date
EA201790506A1 (ru) 2017-08-31
EA039715B1 (ru) 2022-03-03

Similar Documents

Publication Publication Date Title
MX2017002791A (es) Vacuna contra filovirus de virus vaccinia ankara modificado (mva) recombinante.
ZA201707985B (en) Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
MX2020013153A (es) Metodos y composiciones para inducir inmunidad protectora contra la infeccion por virus de inmunodeficiencia humana.
MX2021006931A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
MX361893B (es) Vectores recombinantes de herpesvirus 3 galido (mdv serotipo 2) que expresan antigenos de patogenos de aves y sus usos.
EA201590304A1 (ru) Вакцина рекомбинантного модифицированного вируса осповакцины анкара респираторно-синцитиального вируса
MX2016009072A (es) Fusion de antigenos micobacterianos heterooligomericos.
EA202091516A1 (ru) Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
CL2019000704A1 (es) Vectores de adenovirus canino.
MX2022010588A (es) Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2.
MY173638A (en) Parainfluenza virus 5 based vaccines
WO2016116905A9 (en) Cmv antigens and uses thereof
AR108014A1 (es) Vacuna universal para enfermedades virales y método de vacunación
PH12019500578A1 (en) New promoters
MX2020006471A (es) Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv).
NZ719934A (en) Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
MX2017009889A (es) Vacuna a base del citomegalovirus, expresando la glicoproteína del virus del ébola.
PH12017500419A1 (en) Recoded arbovirus and vaccines
MX2020001655A (es) Vacuna vph.
MX2017014417A (es) Vacunas contra el dengue.
EA202090628A1 (ru) Система экспрессии paramyxoviridae
EA202193150A2 (ru) Филовирусная вакцина на основе рекомбинантного модифицированного вируса осповакцины анкара (mva)
PH12018502430A1 (en) Vaccines
WO2014151687A3 (en) Compositions and methods to treat aids
WO2008118936A3 (en) Method of elicting immune response with a modified mva viral hiv-1 vector